Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

The efficacy of intravitreal interferon alpha-2b for the treatment of experimental endotoxin-induced uveitis.

Afarid M, Lashkarizadeh H, Ashraf MJ, Nowroozzadeh MH, Shafiee SM.

Indian J Ophthalmol. 2016 May;64(5):376-81. doi: 10.4103/0301-4738.185605.

2.

Impending anterior ischemic optic neuropathy with elements of retinal vein occlusion in a patient on interferon for polycythemia vera.

Rue KS, Hirsch LK, Sadun AA.

Clin Ophthalmol. 2012;6:1763-5. doi: 10.2147/OPTH.S33456. Epub 2012 Oct 30.

3.

Retinopathy associated with interferon therapy in patients with hepatitis C virus.

Abd El-Badie Mohamed M, Abd-El Azeem Eed K.

Clin Ophthalmol. 2012;6:1341-5. doi: 10.2147/OPTH.S32469. Epub 2012 Aug 20.

4.

Pegylated interferon-associated severe retinopathy in a patient with chronic hepatitis.

Kang HY, Shin MC.

Korean J Ophthalmol. 2012 Apr;26(2):147-50. doi: 10.3341/kjo.2012.26.2.147. Epub 2012 Mar 22.

5.

Retinopathy associated with adjuvant high-dose interferon-α2b in a patient with resected melanoma: a case report and review of the literature.

Monzon JG, Hammad N, Stevens SD, Dancey J.

Oncologist. 2012;17(3):384-7. doi: 10.1634/theoncologist.2011-0324. Epub 2012 Feb 14.

6.

Pegylated interferon alpha-associated optic neuropathy.

Berg KT, Nelson B, Harrison AR, McLoon LK, Lee MS.

J Neuroophthalmol. 2010 Jun;30(2):117-22. doi: 10.1097/WNO.0b013e3181d8e4af.

7.

Cystoid macular edema and visual loss as sequelae to interferon alpha treatment of systemic hepatitis C.

Sheth HG, Michaelides M, Siriwardena D.

Indian J Ophthalmol. 2010 Mar-Apr;58(2):147-8. doi: 10.4103/0301-4738.60088.

8.

Ischemic optic neuropathy associated with low-dose interferon alfa: report of two cases.

Rodney AJ, Gombos DS, Pagliaro LC, Tannir NM.

Am J Clin Oncol. 2009 Feb;32(1):86-7. doi: 10.1097/01.coc.0000227526.96319.50. No abstract available.

9.

Depression following pegylated interferon-alpha: characteristics and vulnerability.

Lotrich FE, Rabinovitz M, Gironda P, Pollock BG.

J Psychosom Res. 2007 Aug;63(2):131-5.

10.

Bilateral juxtapapillary choroidal neovascularisation associated with interferon alfa treatment of a metastatic cutaneous melanoma.

Garcia-Arumi J, Morral Palau M, Montolio Gil M, Blasco Garrido H, Sararols Ramsay L, Segura García A.

Br J Ophthalmol. 2006 Apr;90(4):516-8. No abstract available.

11.

Is screening for interferon retinopathy in hepatitis C justified?

Cuthbertson FM, Davies M, McKibbin M.

Br J Ophthalmol. 2004 Dec;88(12):1518-20.

12.

Effect of in vitro interferon-beta administration on hepatitis C virus in peripheral blood mononuclear cells as a predictive marker of clinical response to interferon treatment for chronic hepatitis C.

Mochizuki K, Kagawa T, Takashimizu S, Kawazoe K, Kojima S, Nagata N, Nakano A, Nishizaki Y, Shiraishi K, Itakura M, Watanabe N, Mine T, Matsuzaki S.

World J Gastroenterol. 2004 Mar 1;10(5):733-6.

13.

Severe interferon associated retinopathy.

Tu KL, Bowyer J, Schofield K, Harding S.

Br J Ophthalmol. 2003 Feb;87(2):247-8. No abstract available.

14.

Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin.

Jain K, Lam WC, Waheeb S, Thai Q, Heathcote J.

Br J Ophthalmol. 2001 Oct;85(10):1171-3.

Supplemental Content

Support Center